Drug Trial Radar · NCT03989349
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
787
Actual
Start
Jun 30, 2019
Primary completion
Feb 23, 2022
Study completion Sep 26, 2022
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
Conditions
- Moderate-to-Severe Atopic Dermatitis
Interventions
PlaceboDrug
Placebo
NemolizumabDrug
Nemolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) PopulationTime frame: Week 16
- Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Severe Pruritus PopulationTime frame: Week 16
- Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT PopulationTime frame: Week 16
- Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: Severe Pruritus PopulationTime frame: Week 16
Locations
138 sites in 11 countries. Site status is shown where the registry gives one.
Galderma Investigational Site 8749
Birmingham, Alabama
Galderma Investigational Site 8893
Birmingham, Alabama
Galderma Investigational Site 8866
Guntersville, Alabama
Galderma Investigational Site 8808
Scottsdale, Arizona
Galderma Investigational Site 8906
Bell Gardens, California
Galderma Investigational Site 8905
Canoga Park, California
Galderma Investigational Site 8577
Encinitas, California
Galderma Investigational Site 8673
Garden Grove, California
Galderma Investigational Site 8683
Los Angeles, California
Galderma Investigational Site 8907
Newport Beach, California
Galderma Investigational Site 8799
Ontario, California
Galderma Investigational Site 8745
Pasadena, California
Galderma Investigational Site 8658
San Diego, California
Galderma Investigational Site 8536
Santa Ana, California
Galderma Investigational Site 8820
Westminster, California
Galderma Investigational Site 8637
Farmington, Connecticut
Galderma Investigational Site 8875
Delray Beach, Florida
Galderma Investigational Site 8391
Hialeah, Florida
Galderma Investigational Site 8727
Hialeah, Florida
Galderma Investigational Site 8523
Largo, Florida
Galderma Investigational Site 8719
Miami, Florida
Galderma Investigational Site 8656
Miami, Florida
Galderma Investigational Site 8704
Miami, Florida
Galderma Investigational Site 8706
Miami, Florida
Galderma Investigational Site 8203
Tampa, Florida
Galderma Investigational Site 8839
Tampa, Florida
Galderma Investigational Site 8729
Rolling Meadows, Illinois
Galderma Investigational Site 8724
New Albany, Indiana
Galderma Investigational Site 8554
Detroit, Michigan
Galderma Investigational Site 8825
Las Vegas, Nevada
Galderma Investigational Site 8506
Hackensack, New Jersey
Galderma Investigational Site 8741
Buffalo, New York
Galderma Investigational Site 8723
Cortland, New York
Galderma Investigational Site 8733
New York, New York
Galderma Investigational Site 8823
Greensboro, North Carolina
Galderma Investigational Site 8030
Raleigh, North Carolina
Galderma Investigational Site 8747
Cincinnati, Ohio
Galderma Investigational Site 8212
Portland, Oregon
Galderma Investigational Site 8721
Pittsburgh, Pennsylvania
Galderma Investigational Site 8713
North Charleston, South Carolina
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.